ESRD

$317 Mn Organ Preservation Markets by Solution (UW, Custodial HTK, Perfadex), Technique (Static Cold Storage, Hypothermic, Normothermic), Organ (Kidneys, Liver, Heart) - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 24, 2022
Science, Research, Health, Medical Devices, Hospitals, University, Education, Clinical Trials, Glomerulonephritis, Pancreas, Risk, Kidney, CAGR, Medical tourism, USD, Chronic kidney disease, UW, Liver, Kidney failure, Dialysis, ESRD, Polycystic kidney disease, Transplant, Multiple organ dysfunction syndrome, Growth, Patient, Adult, Incidence, Safety, Flushing, Diabetes, Solution, Region, Perfusion, Kidney transplantation, Awareness, Temperature, Dentistry, Pharmaceutical industry, Lexus LS, Non-contact normothermic wound therapy, Heart, Hospital

The global organ preservation market is projected to reach USD 317 million by 2026 from USD 270 million in 2021, at a CAGR of 6.6%.

Key Points: 
  • The global organ preservation market is projected to reach USD 317 million by 2026 from USD 270 million in 2021, at a CAGR of 6.6%.
  • Based on the Solution, the segment is divided into UW, Custodial HTK, Perfadex and Other solutions (EuroCollins and Celsior).
  • Kidneys hold the largest share in the market, by organ type
    Kidneys accounts for a market share in the organ segment.
  • In 2020, the organ transplant centers segment accounted for the largest share of the organ preservation market.

IgA Nephropathy Market Shakes Up with Tarpeyo (Calliditas) Launch and Surge in Physician Prescribing of SGLT2 Inhibitors, Spherix Reports

Retrieved on: 
Monday, March 28, 2022
Optimism, NASA RealWorld-InWorld Engineering Design Challenge, Population, SGLT2, Janssen, Dialysis, ESRD, Biopsy, Lists of people executed in the United States, Canagliflozin, Research, Prescription, AstraZeneca, Nephrology, Dapagliflozin, DAPA, CKD, Physician, EGFR, Awareness, Patient, Medical device, Pharmaceutical industry, IgA nephropathy

EXTON, Pa. , March 28, 2022 /PRNewswire/ -- IgA nephropathy (IgAN) is generally recognized as the most common glomerular nephritis disease globally, impacting many patients and often resulting in ESRD and dialysis or transplant. With a bursting pipeline and the first product, Calliditas' Tarpeyo, recently gaining approval specifically for the treatment of IgAN, there is cause for optimism for patients and prescribers alike.

Key Points: 
  • With a bursting pipeline and the first product, Calliditas' Tarpeyo, recently gaining approval specifically for the treatment of IgAN, there is cause for optimism for patients and prescribers alike.
  • Spherix has been closely tracking the IgAN market for several years, covering physician perspectives, treatment patterns, and pipeline expectations since 2017.
  • This coverage has included in-depth interviews with key opinion leaders (KOLs) and "in-the-trenches" physicians, along with large-scale attitudinal surveys and chart audits of more than 900 patients.
  • In its latest research, Spherix just released the 2022 audit included in RealWorld Dynamix: IgA Nephropathy (US), analyzing 439 IgAN patient records in collaboration with 156 US based nephrologists.

Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors

Retrieved on: 
Monday, March 21, 2022
Nephrology, Therapy, Primary hyperoxaluria, NASDAQ, Johns Hopkins University, Dialysis, DaVita Inc., ESRD, Book, Forward-looking statement, Thomas Jefferson University, Chronic kidney disease, Growth, Business, Board, Kidney, IgA nephropathy, Research, SEC, RNA, Immunoglobulin A, Board of directors, Industry, Technology, FASN, COVID-19, Philippine Council of Evangelical Churches, LDHA, Data, GLOBE, Policy, Efficiency, Atrasentan, Amgen, Pharmaceutical industry, Chinook

SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN to its Board of Directors.

Key Points: 
  • SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN to its Board of Directors.
  • We are pleased to welcome Mahesh to our board as we continue to advance our diversified pipeline of programs for rare, severe chronic kidney diseases, said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics.
  • Previously, Dr. Krishnan served as DaVitas first international chief medical officer in which he oversaw its growth in 10 countries.
  • I am excited to join Chinooks board to help advance its mission of developing precision medicines for kidney diseases, said Dr. Krishnan.

Cavulus CEO Says Rise in Popularity of "Special Needs" Plans Spurs Growth in Medicare Advantage

Retrieved on: 
Thursday, March 17, 2022
Cloud, Organization, MA, University of Pittsburgh Medical Center, ESRD, Marketing, Growth, Multimedia, Johns Hopkins, Phillips, Special needs plan, Single-nucleotide polymorphism, Cardiovascular disease, CEO, Health, Need, Industry, Technology, Diabetes, Blue Cross Blue Shield Association, SNP, Medicare (United States), Medicare, Purdah (pre-election period), Health insurance, Medicaid, UnitedHealth Group

PITTSBURGH, March 17, 2022 /PRNewswire/ -- The Medicare Advantage (MA) program grew by 9% last year gaining 2.3 million new members.

Key Points: 
  • PITTSBURGH, March 17, 2022 /PRNewswire/ -- The Medicare Advantage (MA) program grew by 9% last year gaining 2.3 million new members.
  • According to Patrick Phillips, CEO of Cavulus, a preeminent technology firm in the industry, a key factor in boosting enrollment was an expansion of Special Needs Plans or SNPs (pronounced "snip").
  • Studies show "Special Needs Plans" represent 16% of Medicare Advantage members.
  • ABOUT CAVULUS - Cavulus is a technology driven specialist in Medicare Advantage insurance solutions.

Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Tuesday, March 15, 2022
Survival, Immunoglobulin G, European Medicines Agency, Mortality, Commercial, Quality of life, Program, Patient, NUB, Nasdaq Stockholm, ESRD, EU, Hansa, AMNOG, State, Nasdaq, National Association, Chronic kidney disease, Risk, Dialysis, Kidney transplantation, EMA, Antibody, Hlas, Safety, Transplant, Degenerative disease, Medicine, Kidney disease, Company, Research, Cancer, CEO, DSA, Kidney failure, European Market Infrastructure Regulation, Priority, Kidney, European, Health insurance, Dentistry, Pharmaceutical industry, Medical device, Agency, Imlifidase

This completes, within the foreseen 12 month timeline, the AMNOG (Medicines Market Reorganization Act) process for Idefirix in Germany.

Key Points: 
  • This completes, within the foreseen 12 month timeline, the AMNOG (Medicines Market Reorganization Act) process for Idefirix in Germany.
  • At Hansa, our commitment is to significantly improve the lives of highly sensitized patients in Germany who are waiting for a potentially life-saving kidney transplant," says Sren Tulstrup, President and CEO, Hansa Biopharma.
  • "Highly sensitized kidney patients have previously had very limited access to kidney transplants due to the lack of effective desensitization treatments, and they often have no alternative but to remain on long-term dialysis."
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Fist Assist Devices, LLC Announces Australian Distribution Deal and Sales Launch

Retrieved on: 
Tuesday, March 15, 2022
Medical Supplies, Medical Devices, Health, Surgery, Physical Therapy, General Health, Equity crowdfunding, Technology, Education, Chronic kidney disease, Patient, ESRD, FDA, Pain, Fistula, Ventricular assist device, LLC, Industry, FA-1, Patent, RHCG, Founder, CE marking, Business, Agent handling, Arteriovenous fistula, Radiology, Medical–industrial complex, Medical device

Fist Assist Devices, LLC, announces a three-year affiliation with Regional Health Care Group to commercialize and launch sales of the Fist Assist Model FA-1 device in Australia and New Zealand.

Key Points: 
  • Fist Assist Devices, LLC, announces a three-year affiliation with Regional Health Care Group to commercialize and launch sales of the Fist Assist Model FA-1 device in Australia and New Zealand.
  • The Fist Assist FA-1 device also recently received FDA Breakthrough Device designation for pre-surgical vein dilation for patients with end-stage renal disease (ESRD).
  • We are thrilled to combine forces with Regional Health Care Group for the official launch of the Fist Assist Model FA-1 device in Australia and New Zealand.
  • Fist Assist Devices, LLC is a privately held company from Las Vegas, NV that has developed the Fist Assist wearable technology over the past 30 years.

XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study

Retrieved on: 
Monday, March 14, 2022
Knowledge, NASDAQ, Safety, Xanthine oxidase, Health Canada, Clinical trial, International, Incidence, Cyst, Kidney disease, Marketing, Chronic pain, Diabetic nephropathy, U.S. Securities and Exchange Commission, FDA, Pharmacokinetics, No, Autosome, Quality of life, Food, XRX, NDA, Health, News, Analysis, GLOBE, Coronavirus, Polycystic kidney disease, Patient, ESRD, Form, European Medicines Agency, TSX Venture Exchange, Unitary state, Security (finance), Oxipurinol, Uric acid, COVID-19, Fibrosis, Therapy, CTA, SEC, Diagnosis, Drug discovery, New Drug Application, Pharmaceutical industry, Nasdaq, ADPKD

CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announces that it submitted a clinical trial application (CTA) with Health Canada for a XRX-OXY-101 bridging pharmacokinetics study.

Key Points: 
  • CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announces that it submitted a clinical trial application (CTA) with Health Canada for a XRX-OXY-101 bridging pharmacokinetics study.
  • Additionally, this study will provide data to support future NDA (New Drug Application) marketing submissions to the United States Food and Drug Administration and the European Medicines Agency.
  • Dr. Allen Davidoff stated, XORTX is pleased to have made this regulatory filing step to initiate the launch of the XRX-OXY-101 bridging pharmacokinetic study.
  • At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.

Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine

Retrieved on: 
Wednesday, March 2, 2022
Data collection, Patient, EGFR, Metabolic acidosis, Forward-looking statement, Metabolism, Security (finance), Kidney disease, Securities Exchange Act of 1934, Annual report, Chronic kidney disease, U.S. Securities and Exchange Commission, FDA, SAN, ESRD, Company, Securities Act of 1933, Form 10-Q, Drug Quality and Security Act, Review, Glomerular filtration rate, GLOBE, CRO, CKD, Form 10-K, Pharmaceutical industry

The revised guidance is based on Tricidas evaluation of the current situation in Ukraine which is dynamic.

Key Points: 
  • The revised guidance is based on Tricidas evaluation of the current situation in Ukraine which is dynamic.
  • Tricida believes it will need this incremental time to deal with anticipated disruptions and/or delays in data collection.
  • Tricida does not expect the utility of the data already collected from Ukrainian subjects to be affected.
  • You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Healthmap Announces Kidney Health Management Program Partnership with Highmark Health

Retrieved on: 
Wednesday, March 2, 2022
Accountable care organization, American Association of Clinical Endocrinologists, Chronic kidney disease, Patient, Korea Disease Control and Prevention Agency, Nephrology, Quality of life, Kidney disease, Blue Cross Blue Shield Association, Renal replacement therapy, Solution, KHM, Acos, ESRD, NCQA, Disease, CEO, Kidney, Partnership, Center, Cardiology, GLOBE, CKD, Health insurance, Pharmaceutical industry, HealthMap, Highmark

TAMPA, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Healthmap Solutions, Inc. (Healthmap), an NCQA accredited kidney population health management company, announced today its partnership with Highmark Health (Highmark), a nationally recognized health plan.

Key Points: 
  • TAMPA, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Healthmap Solutions, Inc. (Healthmap), an NCQA accredited kidney population health management company, announced today its partnership with Highmark Health (Highmark), a nationally recognized health plan.
  • This partnership introduces Healthmaps proven Kidney Health Management (KHM) program to Highmark members living with chronic kidney disease (CKD) and end stage renal disease (ESRD).
  • The Healthmap program enhances the physician-to-member relationship to ensure a clinically appropriate, personalized approach, to preemptively intervene to avoid adverse and costly health care events for members with kidney disease.
  • Healthmap Solutions is an NCQA accredited kidney population health management company serving health plans, health systems, accountable care organizations (ACOs), and provider groups seeking a value-based solution to improve the lives of millions of Americans living with kidney disease.

Baxter Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months

Retrieved on: 
Tuesday, March 1, 2022
Health, Medical Devices, Practice Management, Physical Therapy, Managed Care, Research, Science, People, Lists of disasters, Kidney transplantation, University Challenge 2013–14, RA, Critical care, In re Caremark International Inc. Derivative Litigation, MB, Heart failure, Chronic kidney disease, Form, JAMA, Comparison, Physician, APD, Peritoneal cavity, Archive, Quality of life, Disease management, LinkedIn, Multimedia, SEC, Time, Caregiver, Systematic review, PD, JGF, Death, Renal replacement therapy, Blood, Baxter International, Karger Publishers, Medical Affairs Bureau, NYSE, Heart, McAlister, Internal medicine, VS, Form 10-K, Hospital, Twitter, Congress, ESRD, Travel, Peritoneal dialysis, Amia, Meta-analysis, JAMA Internal Medicine, FA, Pharmaceutical industry, Medical device, Patient, Dialysis, Facebook, Nephrology, Baxter, Kaguya, Peritoneal Dialysis, Baxter, PERITONEAL DIALYSIS, BAXTER

In total, Sharesource is currently serving more than 50,000 patients, across more than 70 countries.

Key Points: 
  • In total, Sharesource is currently serving more than 50,000 patients, across more than 70 countries.
  • PD therapy is typically managed by patients in their home, at a time of day that is convenient for them.
  • Baxter, Sharesource, Amia, Homechoice Claria and Kaguya are registered trademarks of Baxter International Inc.
    1 Sanabria M, et al.
  • Comparison of quality of life in patients undergoing hemodialysis and peritoneal dialysis: a systematic review and meta-analysis.